MEK Inhibition Remodels the Immune Landscape of Mutant <i>KRAS</i> Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
Cited by 53
Related Papers
United States Food and Drug Administration Drug Approval Summary
|Clinical Cancer Research|2004|500
SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production
|Journal of Clinical Investigation|2009|401
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Lico A Causes ER Stress and Apoptosis via Up-Regulating miR-144-3p in Human Lung Cancer Cell Line H292
|Frontiers in Pharmacology|2018|61